Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M. +2 more·2001·New England Journal of Medicine
DOI 10.1056/nejmoa011161

Cited by (7,499)

Items 7,401–7,499 of 7,499

  1. The diagnostic value of radiomics based on two-dimensional ultrasound in staging diabetic nephropathy
    Xue-E Su, Jing-Liu, Shanhu Wu, Cui-Liu Lin, Huai-gang Wang, Cheng-bao Peng, Baoyuan Xie, He-fan He · 2026 · BMC Medical Imaging
  2. Protocol for Developing and Validating a Multimarker-Clinical Prediction Model of SGLT2 Inhibitor-Induced Acute eGFR Dip in CKD Stages 3–4: A Three-Stage Urinary Proteomics Study
    Zhi-Yu Duan, Gao Y, Mengjie Huang, Yanjun Liang, Jing Hao, Jie Wang, Guangyan Cai · 2026 · Life
  3. Diabetic nephropathy in Saudi Arabia: Current challenges and management strategies in the era of sodium-glucose co-transporter inhibitors
    Ahmed Abdulaziz Almohammadi, Rami O. Alharbi, Salem S Alhubayshi · 2025 · Saudi Journal of Internal Medicine
  4. Eurasian clinical guidelines for the diagnosis and treatment of cardiorenal syndrome (2026)
    Nataliya P. Mitkovskaya, I E Chazova, Olga A. Sudzhaeva, Elena Grigorenko, О.В. Калачик, Шестакова Лиана Геннадьевна, Е. Ю. Бранковская, М. В. Смолякова, O. Iu. Trushina, Valery I. Podzolkov et al. · 2026 · Eurasian heart journal
  5. Boundary-stratified safety evaluation of large language models for clinical decision support: a synthetic benchmark in chronic kidney disease renoprotective therapy
    Shang-En Yeh, Hsuan‐Jen Lin, Wu‐Wei Lai, Hsuan-Ming Lin · 2026 · Frontiers in Medicine
  6. Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
    Masaru Matsui, Masatoshi Nishimoto, Takaaki Kosugi, Shunsuke Kitamura, Aiko Oda, Masato Kawakami, Akiko Itano, Takayuki Uemura, Hiroyuki Tamaki, Hikari Tasaki et al. · 2026 · Diabetes Obesity and Metabolism
  7. Analysis of Pericoronary Adipose Tissue Attenuation in Patients with Type 2 Diabetes Mellitus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Propensity-Score-Matched Observational Study
    Bryan Wu, Hanyi Joh, Koen Nieman, Ryan Sandoval · 2026 · Biomedicines
  8. Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease
    Chie Saito, Kaori Mase, Shun Ishibashi, Takuya Harada, Ryoya Tsunoda, Toshiaki Usui, Tatsuya Simizu, Kei Nagai, Reiko Ohkubo, Naoki Morito et al. · 2026 · Clinical and Experimental Nephrology
  9. Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease
    Hyoungnae Kim · 2026 · Electrolytes & Blood Pressure
  10. Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium–glucose cotransporter 2 inhibitors
    Melanie Wanigatunga, Michael W. Holliday, Sankar Dass Navaneethan · 2026 · Current Opinion in Nephrology & Hypertension
  11. Effect of GDMT Optimization on KDIGO Risk Categories in HFrEF
    Noel Gilian Panagiotides, Annika Weidenhammer, Suriya Prausmüller, Henrike Arfsten, Daniel Engler, Elias Stix, Georg Spinka, Gregor Heitzinger, Fanny Hoffmann, Cornelia Gabler et al. · 2026 · JACC Advances
  12. Heart failure and renal outcomes with angiotensin receptor blockers compared with calcium channel blockers in patients with chronic kidney disease: a target trial emulation
    Hisashi Noma, Noriaki Kurita, Shingo Fukuma, Takao Fujisawa, Futoshi Oda, Megumi Maeda, Haruhisa Fukuda · 2026 · Heart
  13. Rewiring lipid metabolism in diabetic kidney disease: Pathogenic networks and the therapeutic convergence of natural products
    Ying Pi, Liyuan Wen, Xinyuan Cheng, Xiaona Tang · 2026 · Pathology - Research and Practice
  14. Current Options for Kidney Protection: Are Renin–Angiotensin System Inhibitors Still Relevant?
    Waichi Wong · 2026 · Seminars in Nephrology
  15. From Risk Determinants to Clinical Action
    Tazeen H. Jafar, Anqi Zhu, Oluwabunmi Ogungbe · 2026 · Clinical Journal of the American Society of Nephrology
  16. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Translated into Russian by E.V. Parshina, N.M. Bulanov and A.A. Efimova, edited by E.V. Zakharova
    Article Editorial · 2026 · Nephrology and Dialysis
  17. Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor–based Mitigation of Fluid Retention
    Lucas Maciel de Almeida Corrêa, LM Brandão, Yan Roberth Delmiro Silva · 2026 · Cardiovascular Drugs and Therapy
  18. Managing patients with cardiovascular-kidney-metabolic syndrome: a guideline-driven practical guide for primary care physicians
    Steve Fordan, Imran Afridi, Andrew Garza, Roberto L. Collazo-Maldonado · 2026 · Postgraduate Medicine
  19. More Evidence, More Options, More Questions
    Hiddo J.L. Heerspink, Glenn Matthew Chertow · 2026 · Journal of the American Society of Nephrology
  20. Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease
    Zachary T. Bloomgarden · 2026 · Journal of Diabetes
  21. Effectiveness of AST-120 and probiotics ( lactobacillus ) on renal function in patients with chronic kidney disease: A retrospective cohort study from the TriNetX global collaborative network
    Chi-Hsien Chang, Shang‐Feng Tsai · 2026 · Science Progress
  22. A New Era in the Management of Patients with Diabetic Kidney Disease using Four Pillars of Therapy
    Christodoula Kourtidou, Panagiotis I. Georgianos, Vassilios Liakopoulos, Christos Savvopoulos, Κωνσταντίνος Τζιόμαλος · 2026 · Journal of Atherosclerosis Prevention and Treatment
  23. Real-World Kidney and Glycaemic Outcomes Following Semaglutide Initiation in Adults with Type 2 Diabetes and Mild Chronic Kidney Disease
    Syed Arman Rabbani, Haea Amar Alkoud, Mohamed El‐Tanani, Elmoutaz Azmi Omar Mahmoud, Esraa Elsayed Hassan Ali Mohamed, Ghaith Kasim Zabadi, Hania Muzaffar, Anass Ahmed Qasem · 2026 · Journal of Clinical Medicine
  24. Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol
    Mohan S. Chandra, Thiago Gagliano‐Jucá, Skand Shekhar, Karol Mateusz Pencina, Thomas G. Travison, Rajesh Garg, Marie Elizabeth McDonnell, Kieran F. Reid, Nancy K. Latham, Helen Lam et al. · 2026 · Kidney International Reports
  25. A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy ( STEADFAST )
    Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal Kumar Derebail, Adlette C. Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo Delfini Cançado, Claire C. Sharpe · 2026 · American Journal of Hematology
  26. Diabetic nephropathy: pathophysiology, biomarkers and treatment strategies
    Aditya Singh, Shubhrat Maheshwari, Pavan Kumar, Mamta Agrahari, Arun Kumar Singh · 2026 · Journal of The Egyptian Society of Nephrology and Transplantation
  27. Serum Uric Acid and Hypertension in CKD
    Elisa Russo, Giovanna Leoncini, Cecilia Barnini · 2026 · Updates in hypertension and cardiovascular protection
  28. Antihypertensive Treatment in Chronic Kidney Disease: Current Algorithms
    Marieta P. Theodorakopoulou, Pantelis A. Sarafidis · 2026 · Updates in hypertension and cardiovascular protection
  29. Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications
    Guido Gembillo, Chiara Casuscelli, Alberto La Spada, Ylenia Di Pietro, Giulia Cipressa, Domenico Santoro, Claudia Lo Re · 2026 · Expert Opinion on Pharmacotherapy
  30. Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial
    Valentina O. Püntmann, Eike Nagel, Dietrich Beitzke et al. · 2026 · Nature Communications
  31. Navigating the potassium dilemma: a qualitative study of nephrologists’ strategies for renin–angiotensin–aldosterone system inhibitor preservation and hyperkalaemia management in Spain
    Nicolas Gimenez-Stamminger, Céu Mateus, Thomas Mason, Andrew Harding · 2026 · PLoS ONE
  32. Benefits of renin angiotensin aldosterone system blockage
    Faruk Hilmi Turgut, Emaad M. Abdel‐Rahman · 2026 · Elsevier eBooks
  33. Diabetes in kidney disease progression
    Sheryl Cababat Caberto, Lynn E. Schlanger, Stephen Z. Fadem · 2026 · Elsevier eBooks
  34. Nephroprotectants and Chronic Kidney Disease: Prelude to Protecting Against Progressive Disease
    Karl A. Nath · 2026 · Mayo Clinic Proceedings
  35. Goal-Oriented Hypertension Management in Diabetic and Nondiabetic Patients
    Gregory M. Singer, John Francis Setaro, Henry Richard Black · 2007 · Humana Press eBooks
  36. Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes
    Zurong Zhang, Li Li, Ming Yang, Wei Chen, Li Xiao, Lin Sun, Rajiv Agarwal · 2026 · Nephrology Dialysis Transplantation
  37. Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis
    Jing Liu, Jialu Geng, Jiakun Liu, 胡 蕾, Du Huimin, I J Hung, Jia Fang · 2026 · American Journal of Cardiovascular Drugs
  38. Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase–Aldosterone and Ghrelin–Leptin Axes
    Hsuan-Chu Hsu, Li‐Jane Shih, Yi‐Chou Hou, Kuo‐Cheng Lu · 2026 · Biomolecules
  39. Renin–Angiotensin System Inhibitors and Longitudinal Kidney and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Multicenter Common Data Model Cohort Study
    Yongjin Yi, Seokwoo Park, Jong Cheol Jeong, Ki Young Na, Ho Jun Chin, Sooyoung Yoo, Seok Kim, Chang Hee Jung, Ji Seon Oh, Gakyoung Baek et al. · 2026 · Research Square
  40. Blood Pressure, Kidney Function, and Kidney Mortality Among Mexican Adults
    Doreen Zhu, Pablo Kuri-Morales, Rachel L. Wade, Natalie Staplin, Adrián Garcilazo‐Ávila, Carlos González-Carballo, Raúl Ramírez-Reyes, Diego J. Aguilar-Ramirez, Colin Baigent, Fiona Bragg et al. · 2026 · American Journal of Kidney Diseases
  41. Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice
    Julie A. Lovshin · 2026 · Nephrology Dialysis Transplantation
  42. Angiotensin receptor blocker ameliorates the development of tubulointerstitial injury and fibrosis associated with tubular proteinuria observed in subclinical diabetic kidney disease
    Mariana Rodrigues Campos, Pedro Henrique S. R. Seabra, L. Y. P. OLIVEIRA · 2026 · Frontiers in Pharmacology
  43. Research Progress of Non-Steroidal Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease
    昱成 韩 · 2026 · Journal of Clinical Personalized Medicine
  44. Randomized Clinical Trials of Deutaleglitazar in Healthy Participants and in Patients with Diabetic Kidney Disease
    Vlado Perkovic, Sam L. Francis, Hong Zhang et al. · 2026 · Kidney International Reports
  45. Diabète et Cœur
    Jacques Philippé · 2002 · Cardiovascular Medicine
  46. Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems
    Mohd Danish Ansari, Ashish Vishwakarma, Md. Quamuddin, Mansi Aggarwal, Hashim Khan, Muhammad Fauzi Abd Jalil, Syed Mahmood, Adil Farooq Wali, Sirajunisa Talath, Mohamed El-Tanani · 2026 · Frontiers in Medical Technology
  47. Targeting peptidylarginine deiminases 2 and 4 in diabetic kidney disease: mechanistic rationale and preclinical evidence
    Wiktoria Mallek, Aleksandra Wróblewska-Schmude, Adam Lesner · 2026 · Biochemical Pharmacology
  48. Comparative effectiveness of combination therapy in patients with chronic kidney disease and diabetes mellitus type 2 using real-world data
    Janis Casper, Julian Doricic, Zhejia Tian, Jonas Michael Willerding, Marit Glammeier, Anette Melk, Kai M. Schmidt-Ott, Bernhard M.W. Schmidt · 2026 · Nephrology Dialysis Transplantation
  49. Antidiabetic Properties of Histamine H1 Receptor Antagonists: A Systematic Review
    Michał Radzikowski, Mateusz Maciejczyk · 2026 · Antioxidants
  50. ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome
    Nisha Bansal, Petter Bjornstad, Adam Phillip Bress, Tara I. Chang, Xingxing S. Cheng, Michelle M. Estrella, Alan S. Go, Amy K. Mottl, Sankar Dass Navaneethan, Brendon Lange Neuen et al. · 2026 · Journal of the American Society of Nephrology
  51. Long-term outcomes associated with continued use of ARBs versus CCBs in older adults: a landmark cohort study
    Hisashi Noma, Hiroshi Sunada, Hajime Yamazaki · 2026 · Hypertension Research
  52. A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.
    Shinji KUME, 智史 前川, Shinji KUME · Institutional Repositories DataBase (IRDB)
  53. Promoting Healthy Aging with Gerotherapeutic Medications
    Oh Sung Kwon, Iman M. Al‐Naggar · 2026 · Springer eBooks
  54. GLP-1 RECEPTOR AGONISTS IN CHRONIC KIDNEY DISEASE: NEPHROPROTECTION BEYOND GLYCEMIC CONTROL - A REVIEW OF CURRENT LITERATURE
    Anna Mamach, Aleksandra Woźniak, Patrycja Sobantka, Szymon Mokrzecki, Matylda Król, Katarzyna Aleksandrowicz, Zofia Grodzka, Mateusz Meszka, Ewa Bełc, Karolina Brzezińska · 2026 · International Journal of Innovative Technologies in Social Science
  55. Four Pillars in Type 2 Diabetes and Chronic Kidney Disease G4-G5: Mission Impossible—or Not Too Late to Start?
    Masayuki Yamanouchi, Naoki Sawa, Kengo Furuichi, Takashi Wada · 2026 · Kidney Medicine
  56. Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension
    Akshyaya Kumar Pradhan, Monika Bhandari, Abhishek Kumar Singh, Pravesh Vishwakarma, Kunal Mahajan, Marco Alfonso Perrone, Akash Batta · 2026 · Life
  57. Pharmacological Management of Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Multi-Pillar Cardiorenal-Protective Approach
    Mosrur Ahmed · 2025 · Journal of Prevention Diagnosis and Management of Human Diseases
  58. Efficacy, Safety, and Predictors of Antiproteinuric Response to Finerenone in Patients with Type 2 Diabetic Kidney Disease: A Real-World Study
    Liufang Zhang, Yu Zhou, Zhihua Liu, Ying Xie · 2026 · Research Square
  59. Diabetic kidney disease within the framework of cardio-kidney-metabolic health: a paradigm shift
    Juarez R. Braga, Fatima Ayub, Srikanth Vallurupalli, Nithin Karakala, Joseph Hunter Holthoff · 2026 · Frontiers in Pharmacology
  60. Hypertonie-Management 2003: Confused at a higher level? Bemerkungen zu neuesten Therapiestudien bei Patienten mit hohem Blutdruck
    Thomas Felix Lüscher, Georg Noll · 2003 · Cardiovascular Medicine
  61. Macrophage–Fibroblast Crosstalk in Kidney Injury: A Narrative Review
    Panpan Qiang, Lizheng Han, Ruyan Lv, Zhenfei Dong, Teng Ma, Xiangting Wang, Qingyou Xu · 2026 · International Journal of Molecular Sciences
  62. Acute eGFR Changes With Finerenone Examined in a Prespecified Analysis of FINE-ONE
    David Z.I. Cherney, Tae Won Yi, Hiddo J.L. Heerspink, Linong Ji, Janet B. McGill, Peter Rossing, Katherine R. Tuttle, Jesper N. Bech, Paolo Fiorina, Albert Power et al. · 2026 · Kidney International Reports
  63. Risk Assessability and Recorded Organ-Protective Therapy Gaps in Type 2 Diabetes: A Five-Center Cross-Sectional Study
    wenxuan li, Jinghan Zheng, Wenshan Lv, lili xu, Ke Si, Yuzhao Liu, Shuhui Hu, Shengli Wu, Yuancheng Dai, Qijuan Dong et al. · 2026 · Research Square
  64. The Varanasi Declaration 2026: an India-specific consensus policy framework for integrated cardiovascular–kidney–metabolic care
    Ashutosh Mishra, Pallavi mishra, Sarita Bajaj, Pramila Kalra, Vinaytosh Mishra, Smitha Bhat, Bijay Patni, Vinod K. Abichandani, Faraz Farishta, Vikas Aggarwal et al. · 2026 · The Lancet Regional Health - Southeast Asia
  65. Targeting immune–hemodynamic coupling in early diabetic kidney disease: Mechanisms, biomarkers, and therapeutic opportunities
    Tian Guang LEI, Bingjie Zheng, Yanyu Pang, Jingwen Zhao, Yutong Wang, Mengdi Wang, Wenjing Zhao · 2026 · Biomedicine & Pharmacotherapy
  66. Renin-Angiotensin System (RAS) Inhibitors in High-Risk Patients With Type 2 Diabetes and Cardio-Renal Risk
    Mustafa Jamal Ahmed, Aftab M. Ahmad, Saf Naqvi, Khalid Ahmed, Aisha Ahmed, Zainab Naqvi · 2026 · Cureus
  67. New pharmacologic and interventional horizons in hypertension and nondialysis chronic kidney disease: bridging innovation and clinical translation
    Aikaterini Damianaki, Panagιotis Iliakis, Angeliki Vakka, Emelina Stambolliu, Athanasios Sakalidis, K. P. Dimitriadis, Dimitrios I. Petras, Konstantinos P Tsioufis · 2026 · Journal of Hypertension
  68. Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation
    Alexander Turchin, Lucia C. Petito, Emma Hegermiller, Indhumathy Chelliah, Ryan M. Carnahan, ANDREA R. DEVRIES, Satyender Goel, Maria Cecilia Lansang, Marie Elizabeth McDonnell, Vinit P. Nair et al. · 2026 · BMJ
  69. The Influence of SGLT2 Inhibitors on the Immune System and Inflammatory Processes in Kidney Transplantation
    Andrés García-Sánchez, Pablo Cesar Ortiz‐Lazareno, Leonardo Pazarín–Villaseñor, Elodia Nataly Díaz-de la Cruz, Alondra Mora-Jiménez, Jorge Andrade Sierra, Ernesto Germán Cardona-Muñóz, Sylvia Elena Totsuka-Sutto, Luis Francisco Gómez-Hermosillo, Jorge Casillas-Moreno et al. · 2026 · International Journal of Molecular Sciences
  70. Signaling pathways in the pathogenesis of diabetic kidney disease (review)
    О А Нагибович, Алексей Леонидович Коваленко, О. С. Кетлинская · 2026 · Nephrology (Saint-Petersburg)
  71. The Role of Glycolysis in Diabetic Kidney Disease
    Yifan Wang, Xin Jiang, Liwen Cui, YONGKE YOU, Wenjuan Zhu, Chongfei Jiang, Zhouning Liao, Jianbo Guo, Hao Lu, Baoyi Shao et al. · 2026 · International Journal of Molecular Sciences
  72. An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression
    Lesley A. Inker, Hiddo JL Heerspink, Hocine Tighiouart, Shiyuan Miao, Juhi Chaudhari, Lucia Del Vecchio, Jürgen Floege, Thierry Hannedouche, Enyu Imai, Tazeen H. Jafar et al. · 2026 · Kidney International
  73. Dyslipidemia–Renin–Angiotensin System Crosstalk in Diabetic Kidney Disease: A Critical Narrative Review of Experimental Mechanisms and Clinical Evidence
    Hamid Nasri, Mohammad Reza Chitsazi, Fatemeh Abbasi, Amir Hossein Ashouri, Hanieh Rouzbahani, Seyed Arsham Mirzaei, Faraz Golafshan, Ali Noursina, Farzad Safari · 2026 · Bratislavské lekárske listy/Bratislava medical journal
  74. GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
    Jan Boeckhaus, John Andrew Sayer, Holly R. Mabillard · 2026 · Clinical Science
  75. Nuevos tratamientos farmacológicos en la enfermedad renal crónica: revisión sistemática
    Nayelly del Cisne Urbano-Borja, Karla Michelle Buenaño-Rosero, Dilan Josué Vásquez-Remachi · 2026 · Sanitas. Revista arbitrada de ciencias de la salud.
  76. Tratamiento farmacológico actual de la nefropatía diabética: revisión sistemática
    Evelyn Alexandra Encalada-Bermeo, Jennifer Violetta Bolaños-Soria, Freddy Joel Gonzabay-Rosales, Samantha Elizabeth Palacios-Puga · 2026 · Sanitas. Revista arbitrada de ciencias de la salud.
  77. Cardiorenal Syndrome: From Hemodynamic and Humoral Pathophysiology to New Frontiers in Modulation and Enabling Therapy—Part 2
    Alfredo Mauriello, Valeria Cetoretta, Carmen Del Giudice, Adriana Correra, Anna Chiara Maratea, Renato Gioia, Biagio Liccardo, Giovanni Esposito, Vincenzo Russo, Antonello D’Andrea · 2026 · Biomedicines
  78. Comparative Effectiveness of Sodium-glucose Cotransporter 2 Inhibitors Versus Renin–Angiotensin System Inhibitors in Chronic Kidney Disease
    Yuki Gonda, Yu Horiuchi, Kengo Tanabe · 2026 · The American Journal of Cardiology
  79. Kidney Outcomes With GLP ‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study
    Dvora Rywka Sehtman-Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel · 2026 · Diabetes Obesity and Metabolism
  80. Beyond the 4 pillars: aldosterone synthase inhibition as a fifth frontier in chronic kidney disease management
    Markus Peter Schlaich, Louise Woodhams, Lakshini Yasaswi Herat · 2026 · American Journal of Hypertension
  81. Hypertension disease natural history and healthcare utilization when treatment guidelines do not account for race
    Marika Mae Cusick, Malcolm Barrett, Fernando Alarid‐Escudero, Jeremy D. Goldhaber‐Fiebert, Sherri Rose · 2026 · medRxiv
  82. Astragaloside IV Restores Autophagy and Inhibits Apoptosis for Podocyte Protection in Diabetic Nephropathy by Inhibiting Notch1 Signaling via SIRT6 ‐Mediated Deacetylation
    Qiyu Yue, Chen Yong, Xinran Wang, Yang Shu, Min Yao, Yongfei Yu, 薛玉柏, Rong Deng, Tianlu Chu, Weiwei Tao et al. · 2026 · Phytotherapy Research
  83. Psychosocial and Oxidative Stress and Health of Adults
    Francis B. Annor · 2022 · Digital Archive @ GSU
  84. Valsartan: come versatilità e tollerabilità possono contribuireal contenimento della spesa sanitaria
    Francesco Vittorio Costa · 2011 · Farmeconomia Health economics and therapeutic pathways
  85. Diabetes und Nieren
    Tom H. Lindner · 2013 · Der Diabetologe
  86. Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure
    Pranav Sandilya Garimella, Daniel E. Weiner, Mark J. Sarnak · 2012 · Elsevier eBooks
  87. Antihypertensive and Other Treatments in Early Stages of Diabetic Nephropathy
    W.J. Elliott · 2014 · Springer eBooks
  88. Análise do processo de reparo alveolar em ratos espontaneamente hipertensos (SHR) não tratados e tratados com Losartan: estudo imunoistoquímico e histomorfométrico
    Cassiano Costa Silva Pereira · 2013 · Americanae (AECID Library)
  89. Antihypertensive treatment and the kidney
    Peter W. de Leeuw · 2002 · Cardiovascular Drugs and Therapy
  90. Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure
    Pantelis A. Sarafidis, Panagiotis I. Georgianos, Pantelis E Zebekakis, Athanasios John Manolis · 2014 · Springer eBooks
  91. The Clinical Significance of Blood Pressure Lowering Treatment: Is First-Line Drug Choice Important?
    Guido M. Grassi · 2008 · High Blood Pressure & Cardiovascular Prevention
  92. Diabetische Nephropathie
    Sabine Wolf, Ingo Rettig · 2008 · Elsevier eBooks
  93. Prevención primaria del infarto de miocardio en una unidad territorial de atención primaria. Simulación sobre población atendida basada en una revisión exhaustiva de la literatura
    Joséfina Moraes Arraut, Rosales Alonso, J. L. Clua Espuny · 2005
  94. Management of increased cardiovascular risk
    Jill Hill, Molly Courtenay · 2008 · Cambridge University Press eBooks
  95. Combined Blockade of the Renin Angiotensin System with ACE Inhibitors and AT1 Receptor Antagonists
    Michel Azizi, Joël Ménard · 2004 · Handbook of experimental pharmacology
  96. Consider specific co-morbidities and disease aetiology when treating hypertension in patients with chronic kidney disease
    Adis Medical Writers · 2013 · Drugs & Therapy Perspectives
  97. Preventive Lessons from Hypertension and Myocardial Infarction: Treating Asymptomatic Individuals to Lower the Risk for Subsequent Cardiovascular Events
    Marc Alan Pfeffer · 2014 · Springer eBooks
  98. Gene Expression Profiling in the Investigation of Diabetic Nephropathy
    Katalin Suszták, Erwin P. Böttinger, Kumar Sharma · 2006 · Humana Press eBooks
  99. Use of intensified comprehensive cardiac rehabilitation to improve risk factor control in patients with type 2 diabetes mellitus or impaired glucose tolerance—the randomized DANish StUdy of impaired glucose metabolism in the settings of cardiac rehabilitation (DANSUK) study
    Soja, Anne Merete Boas, Zwisler, Ann-Dorthe Olsen, Frederiksen, Marianne, Melchior, Thomas, Hommel, Eva, Torp-Pedersen, Christian, Madsen, Mette · 2007 · American Heart Journal